✦ LIBER ✦

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

✍ Scribed by Gradishar, William J.; Kaklamani, Virginia; Sahoo, Tarini P.; Lokanatha, Dasappa; Raina, Vinod; Bondarde, Shailesh; Jain, Minish; Ro, Sunhee Kwon; Lokker, Nathalie A.; Schwartzberg, Lee

Book ID: 122517593
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 820 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.08.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Bevacizumab in Combination With Chemothe

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

✍ Ohtsu, A.; Shah, M. A.; Van Cutsem, E.; Rha, S. Y.; Sawaki, A.; Park, S. R.; Lim 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

470 Final results of a phase II study of

470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

✍ S. Glück; C. Lobo; G. Lopes; A. Castrellon; J. Hurley; I. Reis; S. Richman; O. S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Randomised, placebo-controlled, double-b

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

✍ Rougier, Philippe; Riess, Hanno; Manges, Robert; Karasek, Petr; Humblet, Yves; B 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 916 KB

Randomized, Phase II, Placebo-Controlled

Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer

✍ Vergote, Ignace B. (author);Amant, Frederic (author);Chekerov, Radoslav (author) 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB